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Abstract
Background: Pulmonary first pass filtration of particles marginally exceeding ,7 mm (the size of a red blood cell) is used
routinely in diagnostics, and allows cellular aggregates forming or entering the circulation in the preceding cardiac cycle to
lodge safely in pulmonary capillaries/arterioles. Pulmonary arteriovenous malformations compromise capillary bed filtration,
and are commonly associated with ischaemic stroke. Cohorts with CT-scan evident malformations associated with the
highest contrast echocardiographic shunt grades are known to be at higher stroke risk. Our goal was to identify within this
broad grouping, which patients were at higher risk of stroke.
Methodology: 497 consecutive patients with CT-proven pulmonary arteriovenous malformations due to hereditary
haemorrhagic telangiectasia were studied. Relationships with radiologically-confirmed clinical ischaemic stroke were
examined using logistic regression, receiver operating characteristic analyses, and platelet studies.
Principal Findings: Sixty-one individuals (12.3%) had acute, non-iatrogenic ischaemic clinical strokes at a median age of 52
(IQR 41–63) years. In crude and age-adjusted logistic regression, stroke risk was associated not with venous thromboemboli
or conventional neurovascular risk factors, but with low serum iron (adjusted odds ratio 0.96 [95% confidence intervals 0.92,
1.00]), and more weakly with low oxygen saturations reflecting a larger right-to-left shunt (adjusted OR 0.96 [0.92, 1.01]). For
the same pulmonary arteriovenous malformations, the stroke risk would approximately double with serum iron 6 mmol/L
compared to mid-normal range (7–27 mmol/L). Platelet studies confirmed overlooked data that iron deficiency is associated
with exuberant platelet aggregation to serotonin (5HT), correcting following iron treatment. By MANOVA, adjusting for
participant and 5HT, iron or ferritin explained 14% of the variance in log-transformed aggregation-rate (p = 0.039/p = 0.021).
Significance: These data suggest that patients with compromised pulmonary capillary filtration due to pulmonary
arteriovenous malformations are at increased risk of ischaemic stroke if they are iron deficient, and that mechanisms are
likely to include enhanced aggregation of circulating platelets.
Citation: Shovlin CL, Chamali B, Santhirapala V, Livesey JA, Angus G, et al. (2014) Ischaemic Strokes in Patients with Pulmonary Arteriovenous Malformations and
Hereditary Hemorrhagic Telangiectasia: Associations with Iron Deficiency and Platelets. PLoS ONE 9(2): e88812. doi:10.1371/journal.pone.0088812!
Editor: Klaus Brusgaard, Odense University Hospital, Denmark
Received December 22, 2013; Accepted January 13, 2014; Published February 19, 2014
Copyright:  2014 Shovlin et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Funding support was received from National Institute for Health Research: London (NW) Comprehensive Local Research Network (CLS), Imperial
College Biomedical Research Centre (CLS, ML); HHT patient donations; and Imperial BSc project funding (to CLS for BC, VS and JAL). The funders played no role in
the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: c.shovlin@imperial.ac.uk
Introduction
Who is most at risk of paradoxical embolic strokes through the
right-to-left shunts provided by pulmonary arteriovenous mal-
formations (PAVMs)[1]? This question is important not only for
patients, but also to further our understanding of pulmonary
capillary filtration.[2][3]
The pulmonary capillary bed normally provides a first-pass
filtration system for particulate matter forming or entering the
circulation in the preceding cardiac cycle: lung viability is
preserved due to dual arterial supply from systemic arteries,
particularly the bronchial circulation (Figure 1A). [1][2][3]
Pulmonary capillary filtration is used routinely in clinical
diagnostics, using intravenous injection of technetium-labelled
albumin macroaggregates marginally larger than 7 mm erythro-
cytes for nuclear medicine perfusion studies, [4][5] or bubble
contrast in echocardiography.[6]
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PAVMs are anatomical right-to-left shunts between pulmonary
arteries and pulmonary veins, [1] (Figure 1), and by thoracic CT
scanning, are estimated to affect ,1/2,600 individuals. [7] Right-
to-left shunts, including intrapulmonary shunts below the resolu-
tion of CT-scan detection, can be quantified by the circulatory
survival of intravenously injected particles: particles transiting the
shunts bypass the pulmonary capillaries, and reach the left
ventricle and systemic arterial tree. Technetium-labelled albumin
macroaggregates as used for conventional perfusion studies permit
precise quantification of right-to-left shunt size as a proportion of
the cardiac output. [4][8][9][10][11] Contrast echocardiography
can provide broad grades of shunt severity, ranging from Grade 1
(found in at least 7–8% of the general population [12][13]), to
Grade 3 which is more frequently associated with visible PAVMs
on CT scan. [13[14][15][16][17][18] Additionally, because
PAVMs allow deoxygenated pulmonary arterial blood to bypass
the pulmonary capillary bed, arterial PO2 and haemoglobin
saturation (SaO2) are inversely related to the size of the right-to-
left shunt fraction.[1][4][9][10]
Substantial proportions of PAVM patients experience ischaemic
strokes. [1][13][18][19][20][21] Paradoxical embolic events are
more common in patients with Grade 3 shunts, the shunt severity
usually present when PAVMs are visible on CT scan.
[13[14][15][16][17][18] Once PAVMs are sufficiently large for
CT detection, or Grade 3 shunts, there is no clear evidence that
stroke risk is substantially influenced by further increase in shunt
size,[18][20] or by conventional stroke risk factors.[20] Under-
standing which PAVM patients have their strokes at particular
times is important because while PAVM treatment by embolisa-
tion reduces stroke risk, [20] PAVMs are often technically too
Figure 1. Right-to-left shunt and hypoxaemia evaluations. A: Cartoon of the circulations indicating site of the pulmonary capillary filter, the
dual pulmonary and bronchial/systemic arterial supply to lung tissue, and a pulmonary arteriovenous malformations (PAVM, red arrow). B:
Relationship between quantified right-to-left shunt (measured using with 99mTc-labelled albumin macroaggregates (10–80 mm) or microspheres (7–
25 mm)), with same-day oxygen saturation (SaO2), representing 309 paired values in 198 individuals since 1999. The linear regression coefficient of
21.22 (95% CI 21.31, 21.14; p,0.0001) indicates a strong relationship that explains 73% of the total variance in erect SaO2 (adjusted r
2 0.73). The
shunt explained a smaller proportion of the total variance in supine SaO2 (adjusted r
2 0.54, data not shown). C–F: Representative right lateral brain
images following injection of 99mTc-labelled albumin macroaggregates for shunt diagnosis and quantification: C) R-L shunt 48.8% of the cardiac
output, associated with a resting SaO2 of 59%. D) R-L shunt 25%; SaO2 83%. E) R-L shunt 7.7%; SaO2 93.7%. Note the intense activity in the lung
apices as expected. F) R-L shunt 3.3%; SaO2 96%. Note that the gain has been turned up but no cerebral activity is visible. This is the same individual
as in D), with the images taken 6 months before (D) and 3 months after (F) embolisation which obliterated the causative PAVMs.
doi:10.1371/journal.pone.0088812.g001
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small for embolisation, and many treated patients are left with
residual right-to-left shunts.[1][20]
The majority of PAVMs occur as part of hereditary hemor-
rhagic telangiectasia (HHT) [1][4][11][13][18][19][20][21] This
vascular condition [22][23][24] is usually caused by mutations in
endoglin (ENG, HHT type 1), [25] ACVRL1/ALK1 (HHT type 2),
[26] or Smad4 (HHT-juvenile polyposis).[27] PAVMs affect
approximately 50% of HHT patients [21] and are particularly
common in HHT1, with 85% of ENG mutation carriers
demonstrating right-to-left shunts on contrast echocardiography.
[28] HHT also commonly results in hepatic, [29] cerebral [30]
and other visceral AVMs; mucocutaneous telangiectasia that lead
to epistaxis [31][32] and gastrointestinal bleeding [33]; and iron
deficiency which has been recently confirmed to result from
under-replacement of haemorrhagic iron losses.[34] At the outset
of this study, there was no indication that any aspect of HHT
pathology other than PAVM-associated factors would be related to
stroke risk. The general presumption was that ischaemic strokes
developed as a result of paradoxical emboli of venous throm-
boemboli (VTE) either from the systemic venous circulation, [35]
or arising in the PAVM sac, [36] and that stroke risk would
increase with the severity of PAVMs.[19]
The study objectives, to identify new risk factors for ischaemic
stroke in PAVM patients, were achieved. Here, focusing on
PAVM patients with underlying HHT, we provide new insights
into which PAVM patients more commonly have ischaemic
strokes.
Methods
All studies were conducted according to the principles expressed
in the Declaration of Helsinki. Ethical approved was from the
Hammersmith, Queen Charlotte’s, Chelsea, and Acton Hospital
Research Ethics Committee. For LREC 2000/5764: ‘‘ Case Notes
Review: Hammersmith Hospital patients with pulmonary arter-
iovenous malformations and hereditary haemorrhagic telangiecta-
sia (HHT),’’ the ethics committee approved the review of the case
notes for research purposes without seeking individual consents.
For LREC 2000/6308 ‘‘Studies of blood cells derived from HHT
Patients’’, individuals provided written consent for the blood tests
which were not part of standard clinical practice.
The study objective was to identify further risk factors for
ischaemic stroke in PAVM patients. Our previous studies in a
PAVM population in which 205/219 (93.6%) had HHT,
demonstrated an ischaemic stroke rate of 13.7%. [20] A
population of 450 would therefore have 90% power to detect a
difference of 0.45 standard deviations for tested variables at the
5% significance level (two-tailed). As it was not clear whether such
stroke rates and hence power calculations would apply to PAVM
cohorts with a greater number of sporadic cases, for the current
study, analyses were restricted to PAVM patients with HHT.
Study Cohort
The cohort represents 497 consecutive adult PAVM patients
with a clinical diagnosis of HHT,[37] and radiologically-con-
firmed PAVMs, reviewed May 1999-February 2013 in a pan-UK
tertiary service (www.imperial.ac.uk/nhli/hht_pavm_
patient).
Assessments were performed in keeping with clinical service
practice. As detailed below, based on existing protocols and a
systematic literature review [38], from the outset of the study in
1999, individuals presenting with definite or possible HHT [37]
and/or PAVMs underwent detailed same-day clinical assessments
including imaging (chest x-ray and thoracic CT scans if not
performed previously); pulmonary function testing including
measurement of oxygen saturation by pulse oximetry (SaO2);
blood tests; and shunt studies, before subsequent embolisation of
PAVMs where appropriate. Over the 14 years of the study,
routine clinic protocols were updated according to new published
evidence, and results of additional research study protocols.
Standard Clinical Assessments
Imaging. Chest x-rays were performed for all patients on
presentation and in follow up. At the outset of the study in 1999,
based on a literature review of published PAVM cases [38] and
established service practices,[10] thoracic CT scans were only
performed if there were relevant symptoms (respiratory or
neurological such as transient ischaemic attacks, strokes or brain
abscess); or if there was evidence of hypoxaemia or a rightto-left
shunt by screening methods (see below). By 2002, it was apparent
that very small PAVMs with feeding artery diameters ,3 mm
could be associated with ischaemic stroke and/or brain
abscess,[20] and CT scans were introduced as routine screening
for all patients, if not performed previously, initially using adapted
Remy protocols.[39] The radiation burden has been substantially
decreased, and the resolution improved, by the use of newer
multislice, multidetector CT, which limit x-ray exposure to a single
short breath-hold acquisition, and which allow multiplanar and
three dimensional reconstructions of the data.[40]
Although we were aware that other PAVM groups internation-
ally were introducing contrast echocardiography as a screening
tool, [41] and research studies were performed, [42] contrast
echocardiography was not introduced routinely into the service for
PAVM screening. As discussed at the time, [43][44] this was
because of the high frequency of apparent false negatives where
PAVMs were not identified by subsequent angiography, con-
sidered to be the gold standard for detection of PAVMs (10/25
cases in [41]; 20% in [45] and 6/11 in [46]); the frequency with
which the studies were positive requiring subsequent CT
evaluations [1][44]; service logistics; patient preference for the
speed and cannula free CT scan; research study variability in grey
scale and spectral Doppler of the carotid artery post Echovist
injection on repeated studies; [42][47] limited correlations with
validated methods of right-to-left shunt quantification; [42][47]
and provocation of angina with electrocardiographic ST segment
depression in a patient with a large right-to-left shunt. These
research studies were never formally published due to the untimely
death of the late Professor Martin Blomley.[48]
Right-to-left (R-L) shunt measurements. These were
routinely made at the outset of the study using established
departmental protocols. [4][8][9][10][49][50] For these nuclear
medicine quantifications, 71–150 MBq (median 100 [IQR
93,106]) MBq of 99mtechnetium-labelled albumin macroaggre-
gates were injected into the antecubital vein. The shunt was
formally quantified by the proportion of radioactive tracer
detected over the right kidney (posterior view), adjusted for dose
injected, and assuming the right kidney receives 10% of cardiac
output (kidney dose method). [4][11] By 2002, it was apparent that
very small PAVMs with right-to-left shunts below the usual
diagnostic cut off [10] could be associated with strokes and brain
abscess: this was formally confirmed as a lack of association with
paradoxical embolic endpoints. [20] Routine right-to-left shunt
measurements were phased out after 2006 in view of these data;
the cerebral images (Figure 1C–F); patient reports of headaches
provoked by the scans; and further validations of oxygen
quantification methodologies.
Other clinical assessments. General clinical variables
defined at the time of initial clinic assessment included a full
PAVMs and Strokes
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symptomatic review [51]; full past medical, [20][52] pregnancy,
[53] and family [53][54] histories; histories of current or ex-
smoking; full drug history with a particular focus on treatments
used for HHT haemorrhage (in this series, female hormones,
tranexamic acid and iron/blood replacement (oral and intrave-
nous iron; blood transfusions)); hypertension on treatment or blood
pressure .140/90; atrial fibrillation on treatment or ECG; and
known diabetes mellitus, hypercholesterolaemia or cardiac disease.
Headaches were defined as migrainous for patients on migraine
treatment, or describing recurrent headaches with aura and/or
teichopsia.[55]
Strokes were defined as clinically evident, focal cerebral deficits
of rapid onset, at least 24 hs in duration. This population have
heightened susceptibility to other strokes and stroke-like pathol-
ogies [1][12][13][14]. We have previously addressed haemor-
rhagic strokes, [54] brain abscesses,[20][56] and migraines, [55] in
the population. For the current study which focused specifically on
ischaemic strokes, an independent report of a causative infarct on
clinical post stroke cross-sectional imaging was required to assign
ischaemic aetiology.
Polycythaemia, and anaemia due to iron deficiency, are
common problems in PAVM and HHT patients.
[14][15][16][51] Throughout the study, blood tests included full
blood counts with haematinics, routine biochemistry, coagulation
screens, and iron assessments (serum iron and transferrin
saturation index (Tf SI)). To optimise clinical management, blood
tests were taken at standardised times to minimise variability due
to diurnal variation in iron levels, which at the study outset was
anticipated to lead to daytime falls in iron [57] Following the
identification of venous thromboemboli risks and elevated FVIII in
a research study protocol [52], Factor VIII:Ag was included in
routine blood tests from 2002, but to avoid confounding variables,
not within 6 months of a known confounding state such as VTE,
infection, therapeutic embolisation, surgery or pregnancy.[52][57]
Our interim 2006 analyses demonstrated multiple associations
between clinically relevant endpoints and iron treatment and/or
iron deficiency (Shovlin, Jackson, and Kulinskaya, 2006 unpub-
lished). Recognising that identifying incorrect associations could
lead to potentially detrimental clinical care, the iron deficiency/
treatment associations were not published in the relevant manu-
scripts. [20][52][58][59] Instead, extensive literature searches to
identify potential mechanistic routes were undertaken, and
relevant clinical research study protocols performed to define
why iron deficiency was present; [34] examine relationships with
hypoxaemia compensations; [51] and explore potential mechan-
isms for associations with thrombotic and other clinical endpoints
([60] CIBA Foundation searches; current manuscript; Mollet et al
manuscript in preparation). For the clinical service, ferritin, which
had not been measured initially due to concerns about interpreta-
tion in populations at high risk of hepatic AVMs,[61][62] was
measured routinely from 2006.
Embolisation. 262 (62.1%) patients underwent embolisation
treatment of PAVMs, [40][58][63] with embolisation not
indicated in the remainder primarily due to PAVMs with feeding
arteries too small for treatment. Other reasons for no embolisation
include previous maximal treatment elsewhere, contraindications
(four with very severe pulmonary hypertension,[58] with one on a
liver transplant waiting list), or patient preference. Pulmonary
artery pressures (PAP) were measured in 262 patients undergoing
embolisation, recorded by a centrally-placed catheter prior to
contrast injection.[40][58][63]
Study Specific Methods
Oxygen saturation and validations. Pulse oximetry had
been introduced into the PAVM clinical service more than a
decade earlier [10] because of patient preference compared to the
repeated arterial punctures required to obtain arterial blood gases.
Pulse oximetry at 1 minute intervals for 10 minutes standing, with
the mean of the recordings at minutes 7, 8, 9 and 10, had been
validated as a robust measure of PAVM severity, better reflecting
right-to-left shunt size than SaO2 in other postures, or on
exercise.[10]
For the current study, Table 1 demonstrates that the replicate
four values following 7, 8, 9 and 10 minutes standing were highly
reproducible. To further validate the mean value for use in the
current manuscript, the mean SaO2 was compared in the
subgroup of patients with same-day right-to-left shunt measure-
ments. Same-day shunt measurements were available in 198 cases
and ranged from 0.7–48.8% of cardiac output (median 5.3%). The
right-to-left shunt explained 73% of the total variance in mean
SaO2 (Figure 1B).
Blood tests and validations. Iron deficiency is a common
problem in HHT patients [14][15][16] A low serum ferritin
defines iron deficiency, but as discussed previously by ourselves
[60] and others, [61][62] iron deficiency may be present in the
setting of a normal or high ferritin due to concurrent pathologies:
Inflammation, liver pathology, kidney disease, malignancy,
rheumatoid disease, hyperthyroidism, heavy alcohol intake, and
hepatic AVMs are all associated with high ferritin concentrations
despite severe iron deficiency. [60][61][62] Additionally, iron
deficiency may be difficult to assess in the PAVM/HHT patients,
because secondary polycythaemia in hypoxaemic patients masks
anticipated anaemia. [35][51][60] To evaluate if low serum iron
levels were capturing similar iron deficient cohorts to low serum
ferritin, haematinic variables were examined in patients with
ferritin,15 mg/L, ferritin,20 mg/L, or serum iron ,11 mmol/L
irrespective of ferritin. As shown in Table 2, the iron-deficient
haematinic variables were indistinguishable between these three
iron-deficiency definitions, and all differed substantially from the
group without evidence of iron deficiency. We concluded that it
was appropriate to use low serum iron, measured during the
standardised afternoon timepoints, as a marker of a clinically
relevant iron deficient state.
Platelet aggregation. Following identification of a poten-
tially highly relevant manuscript describing modified platelet
aggregation responses to serotonin (5 hydroxytryptophan, 5HT) in
iron deficient patients[64] platelet aggregation responses were
examined in a subgroup of HHT patients. The maximal %
aggregation, and slope representing rate of platelet aggregation
were measured with light transmission (Born) aggregometry
(Helena Bioscience APACT4) in platelet rich plasma (PRP) within
2 hours of blood sampling: 10 mls of blood from consenting
individuals was collected into citrate tubes, and centrifuged at
900 rpms for 10 mins to generate platelet rich plasma. To
generate platelet poor plasma, the remaining blood was cen-
trifuged at 3,000 rpms for a further 10 mins. The turbid platelet
rich plasma and clear platelet poor plasma were used for APACT4
turbidity reference settings representing 0 and 100% aggregation
respectively. For experimental assays, fresh solutions of adenosine
diphosphate (ADP, Helena Biosciences), and serotonin (5HT,
Sigma) were prepared, and serial dilutions used to generate
working concentrations. For ADP these were 50 mM, 20 mM,
10 mM, and 5 mM; for 5HT 20,000 mM, 2,000 mM, 400 mM,
200 mM and 20 mM. For aggregation assays, 25 ml of agonist was
added to 225 ml of platelet rich plasma, and aggregation over
300 s measured by the loss in plasma turbidity as platelets
PAVMs and Strokes
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aggregated and sedimented. All measured read outs were entered
into an Excel database and blood test values added, before
transferring to STATA for statistical analyses which used absolute
iron/ferritin values (for graphical illustration, patients were divided
into groups).
Very careful patient selection was used to permit utilisation of
serum ferritin, because in Woods et al, [64] platelet aggregation
reflected iron status over preceding weeks and not days. Multiple
disease states are associated with high ferritin concentrations
despite severe iron deficiency both in the general population,
[61][62] and in HHT patients [60] who have normal iron
handling and appropriate hepcidin levels. [34] Potential partici-
pants were therefore selected if (based on current nosebleeds[65]
and prior history/investigations), they were anticipated to be
consistently iron deficient or non iron deficient, not taking anti-
platelet agents, [66] not transfused or receiving intravenous iron,
[60] and without known concurrent inflammatory or hepatic
disease. [60][61][62] Due to logistics of same-day blood sampling
and processing, platelet assays were performed before the routine
ferritin and iron results were known.
Statistical analyses. Statistical analyses were performed
using STATA IC version 12 (Statacorp, Texas), with adjustments
for multiple testing performed using the false discovery rate
(FDR).[67] Datasets utilised presentation values (non stroke
patients), or timepoint closest to the stroke (stroke patients).
Age/gender and iron-adjusted odds ratios were calculated by
adding each variable to separate models which were simulta-
neously examining the associations of first ischaemic stroke with
age and gender, or serum iron: p values were calculated by post-
estimation Wald tests. Final models were confirmed using receiver
operating characteristic (ROC) analyses. Variance contributions in




Full demographics of the series are presented in Table 3. The
median age of the 497 consecutive and unselected PAVM/HHT
patients was 47 (IQR 35, 60)ys. 302(60.8%) were female.
231(46.4%) had recognisable neurovascular risk factors, including
185(37.2%) current/former smokers, 75(15.1%) with documented
or treated hypertension, and smaller numbers with hypercholes-
terolaemia, diabetes, or arrhythmias. SaO2 ranged from 59–100%
(median 94.75%, IQR 91,96%). Due to HHT bleeding, pre-
dominantly from the nose, [34] 137(28%) had used iron tablets,
17(3.5%) had used intravenous iron, and 42(8.6%) had been
transfused.
Table 1. SaO2 measurement reproducibility.
Overall Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5
Number of datasets 522 104 104 104 104 103
SaO2 erect (%): mean (SD) 93.9 (4.1) 86.9 (3.7) 93.2 (1.0) 95.4 (0.72) 96.5 (0.6) 97.3 (0.68)
SD of 4 replicates (%): mean (SD) 0.40 (0.44) 0.60 (0.74) 0.37 (0.29) 0.34 (0.30) 0.30 (0.31) 0.38 (0.30)
SaO2 values measured by pulse oximetry following 7, 8, 9 and10 minutes standing. The variability within these measurements has not been presented previously. 522
consecutive datasets for the 165 PAVM patients first presenting between 2006 and 2010 were analysed and represent their datasets at presentation and in follow up. To
illustrate reproducibility across all severities of hypoxaemia, datasets were divided into quintiles based on SaO2, each with over 100 datasets. SD, standard deviation.
doi:10.1371/journal.pone.0088812.t001
Table 2. Comparison of iron deficiency classifications.
Median Lower quartile (Q1) Upper quartile (Q1)
No ID ferr,15 ferr ,20 iron ,11 No ID ferr,15 ferr ,20 iron ,11 No ID ferr,15 ferr ,20 iron ,11
Age (yr) 48 47.5 47.5 52 35 37.5 39 43 62 52.5 54 61
SaO2 (%) 95 95 94.6 94.9 92 90.5 89.3 92 96.5 96 95.5 95.8
BMI (kg/m2) 25.8 25.1 25.3 26.3 22.9 21.9 21.9 21.9 28.2 28.3 29.8 30.2
Haemoglobin (g/dl) 15.1 12.8 12.9 13 13.9 11.6 12.3 11.9 16 13.7 13.8 14.2
Haematocrit 0.44 0.4 0.4 0.4 0.41 0.38 0.39 0.38 0.47 0.42 0.43 0.44
MCV (fl) 89.6 84.8 85 85 86.8 73.4 73.9 76.4 92.8 86.9 87.4 87.4
MCH (pg) 30.7 26.6 27.2 27.6 29.4 22.6 22.8 23.9 31.8 29 29.1 29.2
MCHC (g/dL) 34 32.1 32.2 32 33.3 30.7 30.6 31 34.7 33.1 33.4 33.2
Serum iron (mmol/L) 18 7 8.5 7 16 4 4 4 24 13 13 10
Serum TfSI (%) 30.5 10.5 15 11 27 6 6 6 44 17.5 21 15
Serum ferritin mg/L 51 7 9.5 19 31.5 5.5 6 7 93 10.5 14 40
Oxygen content (mls/dl) 18.8 16 16 16.3 17.4 14.9 14.8 14.8 20.1 17.4 17.6 18.1
For patients presenting between 2006 and 2010, iron deficiency was assigned as absent (No ID) if ferritin, iron and TfSI were all clearly in the normal range
(ferritin.20 mg/L, serum iron.11 mmol/L and TfSI.20%, N= 93). The groupings to examine iron deficiency were ferritin ,15 mg/L (ferr,15, N = 20); ferritin ,20 mg/L
(ferr,20, N = 26); and serum iron ,11 mmol/L (iron ,11, N = 50). BMI, body mass index. MCV, mean corpuscular volume. MCH, mean corpuscular haemoglobin. MCHC,
mean corpuscular haemoglobin concentration. TfSI, transferrin saturation index.
doi:10.1371/journal.pone.0088812.t002
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Paradoxical embolic events
No neurological deficits or myocardial ischaemic symptoms
were reported by the patients following perfusion study quantifica-
tion of the right-to-left shunt. However, larger shunts were
associated with substantial cerebral microvascular impaction, and
this reduced after PAVM embolisation (Figure 1C–F).
Sixty-one individuals (12.3%) experienced at least one clinical
stroke confirmed as ischaemic in aetiology at median age 52 ys
(IQR 41–63 ys). By Oxford/Bamford classification, 43/61 (70.5%)
were partial anterior circulation syndromes, 17/61 (27.9%) were
partial posterior circulation syndromes, and one patient had a
lacunar circulation syndrome (Table 4). There was no difference in
ages between the stroke distribution types (Table 4).
Conventional stroke risk factors
Almost half of the ischaemic strokes (29/61, 47.5%) occurred in
lifelong non smokers without any documented conventional stroke
risk factors (hypertension; hypercholesterolemia, diabetes, or
arrhythmias). Ischaemic strokes were no more frequent in patients
with one or more conventional risk factors (32/231) than
those without any risk factors (29/266, x2 p= 0?42). In age/
gender-adjusted logistic regression, none of the conventional
Table 3. Population Demographics.
No stroke Ischaemic stroke Total Mann Whitney
N median mean N median mean N median mean p value
Ischaemic stroke 436 0 0 61 1 1 497 0 0.12 —
Age (yr) 436 46 46.4 61 51 51.5 497 47 47.0 0.025
Gender (% female) 436 1 0.60 61 1 0.69 497 1 0.61 0.17
Smoking 436 0 0.37 61 0 0.38 497 0 0.37 0.94
Hypertension 434 0 0.14 61 0 0.21 495 0 0.15 0.15
Venous thromboemboli 436 0 0.053 61 0 0.049 497 0 0.052 0.91
Diabetes mellitus 436 0 0.011 61 0 0.033 497 0 0.014 0.19
Atrial fibrillation or arrythmia 436 0 0.014 61 0 0.016 497 0 0.014 0.87
Hypercholesterolemia 435 0 0.016 61 0 0.016 496 0 0.016 0.97
Ischaemic heart disease 436 0 0.0046 61 0 0.049 497 0 0.01 0.0011
Myocardial or valvular disease 436 0 0.0092 61 0 0 497 0 0.008 0.45
High output cardiac failure 436 0 0.0046 61 0 0 497 0 0.004 0.6
Brain abscess 436 0 0.096 61 0 0.098 497 0 0.10 0.96
Migraines 435 0 0.35 61 0 0.33 496 0 0.35 0.74
Ever transfused (%) 430 0 0.081 57 0 0.12 487 0 0.086 0.3
On iron treatment (oral) 431 0 0.27 58 0 0.36 489 0 0.28 0.14
Ever used intravenous iron 425 0 0.033 57 0 0.053 482 0 0.035 0.45
Ever used tranexamic acid 425 0 0.028 57 0 0.035 482 0 0.029 0.77
Ever used hormones 423 0 0.10 57 0 0.16 480 0 0.11 0.22
Oxygen saturation (SaO2, %) 414 95 92.9 57 94 91.8 471 94.8 92.7 0.28
Hemoglobin (g/dl) 404 14.2 15.4 60 13.8 17.5 464 14.1 15.7 0.25
Platelets (x109/dl) 405 267 275.5 60 272.5 284.8 465 268 276.7 0.57
Serum iron (mmol/L) 364 12 13.7 55 9 10.7 419 12 13.3 0.025
Serum transferrin saturation index, TfSI(%) 364 20 21.7 56 15 18.4 420 19 21.2 0.094
Ferritin (mg/L) 214 29.5 49.5 28 34.5 49.8 242 30 49.6 0.55
C-reactive protein, CRP (iu/ml) 275 2 3.49 35 2 7.25 310 2 3.91 0.59
Prothrombin time, PT (s) 385 10.7 10.9 54 10.5 11.2 439 10.7 11.0 0.08
Activated partial thromboplastin time, APTT (s) 381 26 26.1 54 25.65 25.8 435 26 26.1 0.27
Thrombin time, TT (s) 369 14.6 14.6 52 15 15.1 421 15 14.7 0.07
Fibrinogen (g/L) 381 3.03 3.11 58 3.34 3.48 439 3.07 3.16 0.013
Factor VIII:Ag, FVIII (iu/ml) 240 1.50 1.63 40 1.73 1.87 280 1.52 1.66 0.07
Von Willebrand Factor, VWF (iu/ml) 177 1.01 1.25 25 1.1 3.00 202 1.025 1.47 0.36
Pulmonary artery pressure (systolic), PAP, mmHg 217 23 24.1 45 23 24.1 262 23 24.1 0.69
Pulmonary artery pressure (diastolic), PAP, mmHg217 8 8.2 45 7 7.82 262 7 8.16 0.63
Pulmonary artery pressure (mean), PAP, mmHg 214 14 14.5 45 13 14.0 259 14 14.4 0.51
Series Indicator 436 2 1.8 61 1 1.63 497 2 1.75 0.13
Demographics of individual and combined series, with p values calculated by Mann Whitney. N, number of recordings of variable in series.
doi:10.1371/journal.pone.0088812.t003
PAVMs and Strokes
PLOS ONE | www.plosone.org 6 February 2014 | Volume 9 | Issue 2 | e88812
neurovascular risk factors were associated with ischaemic stroke
risk (Table 5).
Ischaemic strokes were more common in patients who had
experienced at least one myocardial infarction (Table 5). This
association persisted after adjustment for all other measured
variables, and no other measured variable could replace
myocardial infarction in the model, in keeping with a common
paradoxical embolic aetiology.[68] However, only five patients
had myocardial infarctions, three of whom had also experienced
an ischaemic stroke.
Surprisingly, in crude and age/gender adjusted analyses, there
was no association between ischaemic stroke and VTE (Table 5).
Association between ischaemic stroke and iron
deficiency
Ischaemic strokes were more common in patients with low
serum iron (Table 5). This association was maintained when
adjusted for all other variables. Quadratic regression suggested a
near linear inverse relationship between ischaemic stroke risk and
serum iron (Figure S1a). The age/gender adjusted odds ratio of
0.96 [95%CI 0.92, 1.00], per mmol/L increase in serum iron,
Table 5) implies that a serum iron of 6 mmol/L would be
associated with approximately double the risk of stroke compared
to a serum iron level in mid-normal range. Iron-stratified Kaplan
Meier survival curves are illustrated in Figure 2A.
The study was not powered to evaluate the differences between
the groups with and without conventional risk factors, but
subgroups analysis suggested that stroke associations with low
iron were not confined to patients without known cardiovascular
risk factors: The age/gender adjusted odds ratios odds ratios were
0.95 (95%CI 0.90, 1.01, p = 0.075) for the group with known
ischaemic stroke risk factors, and 0.97 (95% CI 0.93, 1.03,
p = 0.32) for the group without.
Other associations with stroke risk
It is usually considered that larger right-to-left shunts are
associated with an increased risk of neurological complications.
Risk are definitely increased in patients with Grade 3 shunts by
transthoracic contrast echocardiography (TTCE), compared to
shunts of lesser severity.[18] The majority of patients in this study
would be expected to have a grade 3 shunt, because they had
PAVMs which were visible on CT. [13][14][15][16][17][18]
Surprisingly, crude analyses demonstrated no association between
lower SaO2 reflecting larger shunts, and stroke risk (Table 3). In
iron-adjusted analyses, there was a marginal association between
low SaO2 and stroke risk (Table 5): the iron-adjusted odds ratio
(0.96 [95%CI 0.92, 1.000]) implied that the risk of stroke would
increase ,1.4 fold with SaO2 90% and ,2.3 fold with SaO2 80%,
for the same degree of iron deficiency.
ROC analyses suggested that in the subgroup of patients with
pulmonary artery pressure (PAP) measurements, stroke risk was
greater in the setting of lower PAP(mean), supporting our earlier
PAVM stroke studies which identified enhanced stroke risk with
low PAP. [20] In these ROC analyses, stroke risk was also greater
with lower serum iron, lower SaO2, higher fibrinogen (the
predominant plasma protein for platelet adhesion[69]), and in
women (Figure 2B). These associations were evident once adjusted
for the presence of all other variables in the ROC model, and
therefore making independent contributions to stroke risk in the
model.
We concluded that risk factors were pointing away from
conventional neurovascular aetiologies, paradoxical embolism of
venous thrombi, or shunt severity, towards a process influenced by
iron deficiency and paradoxical emboli of platelets.
Platelet aggregation
Given the established efficacy of anti-platelet therapy in
prevention of ischaemic stroke, [70] we hypothesised that iron
deficiency may enhance platelet activity. No relevant articles were
identified through PubMed. From the CIBA Foundation Sympo-
sium back-catalogue, we identified an early report[64] which we
believe may have been hitherto underappreciated. Supporting our
hypothesis, these authors [64] demonstrated enhanced platelet
aggregation responses to 5HT in 19 anaemic iron deficient
patients (Hb 8.7960.24 g/dl; serum iron 3.860.32 mmol/l)
compared to controls. [64] The aggregation response corrected
in all patients retested following treatment of their iron deficiency.
[64] 5HT was examined because iron deficiency impaired the
activity of the iron-containing platelet monoamine oxidase that
metabolises 5HT; resuspension studies confirmed altered aggrega-
tion responses were due to the platelet, not the plasma.[64]
These findings were replicated in a carefully selected subgroup
of patients. Controls displayed secondary aggregation waves to
ADP (Figure 3A), but not 5HT (Figure 3B). In contrast, severely
iron deficient patients displayed delayed secondary aggregation
waves to 5HT, (Figure 3C) partially correcting with improved iron
indices (Figure 3D).
To examine further, participants were assigned to two group-
ings defined by serum ferritin: iron deficient (ferritin 2–17 (median
8)mg/L, n= 7) and controls (ferritin 24–98 (median 38)mg/L,
n = 8). No individual had a ferritin between 17 and 24 mg/L. ADP
induced similar dose-dependent aggregation in iron deficient
patients and controls (Figure 4A, Figure 4B). However, iron
deficient HHT patients displayed enhanced total aggregation to
5HT over a five minute period (Figure 4C). The iron deficient
Table 4. Details of clinical ischaemic strokes.
N Gender (% female) Age at stroke median (range)
Total anterior circulation TACS 0 — ----
Partial anterior circulation PACS 43 65?1 51 (24–77)
Partial posterior circulation POCS 17 53?1 52 (25–89)
Lacunar circulation* LACS 1 100 58
Total ALL 61 51?5 51 (24–89)
*Note that silent lacunar infarcts, or silent infarcts at other sites, were excluded by the study methodology. Data exclude four iatrogenic strokes of known aetiology (one
following thrombus injection through giving set; one at time of cerebral angiography; one at time of pulmonary angiography; and one progressive following
stereotactic radiotherapy), but otherwise include all first clinical strokes of ischaemic aetiology.
doi:10.1371/journal.pone.0088812.t004
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group also displayed faster rates of aggregation in response to 5HT
(Figure 4D).
The variables of 5HT aggregation and aggregation rate were
skewed and normalised by log(ln) transformation (SFigure2). In
univariate and multiple regression, serum iron was inversely
related to (ln)aggregation (Table 6A). Serum iron was also
inversely related to (ln)rate of aggregation. These inverse
associations persisted after adjustment for 5HT dose and ferritin
(Table 6B). Using MANOVA to adjust for participant and 5HT
concentration, either iron or ferritin explained 14% of the total
variance in (ln)5HT aggregation rate (p = 0?039 (iron); p = 0.021
(ferritin)).
Discussion
In this study, paradoxical embolic strokes associated with the
right-to-left shunts of CT-evident PAVMs were shown to be
associated with low serum iron levels which approximately
doubled age-adjusted stroke risks. Although there are multiple
metabolic and physiological associations with iron deficiency, and
the current study does not demonstrate causality, platelet data
presented here and four decades ago, [64] highlight one
consequence of iron deficiency that would be highly relevant to
stroke pathogenesis, namely enhanced platelet aggregation
responses.[71]
Table 5. Adjusted odds ratios for ischaemic stroke risk.
Age and gender-adjusted Serum iron-adjusted
N Odds Ratio p value N Odds Ratio p value
Age — — — 419 1?02 (1?00, 1?03) 0?13
Gender — — — 419 1?40 (0?75, 2?58) 0?29
Smoking 497 1?08 (0?62, 1?91) 0?78 419 0?94 (0?52, 1?70) 0?84
Hypertension 495 1?32 (0?65, 2?67) 0?44 417 1?27(0?60, 2?68) 0?54
Diabetes 497 3?34 (0?61, 18?2) 0?16 419 3?10 (0?54, 17?6) 0?2
AF and other arrythmias 497 1?05 (0?12, 9?21) 0?96 419 1?07 (0?12, 9?56) 0?95
Hypercholesterolemia 496 0?78 (0?09, 6?65) 0?82 418 1?24 (0?14, 10?6) 0?85
Myocardial infarction (MI) 497 8?86 (1?41, 55?5) 0?02 419 22?6 (2?26, 226?7) 0?008
Brain abscess 497 0?98 (0?39, 2?46) 0?97 419 0?88 (0?33, 2?35) 0?02
Migraines 496 0?87 (0.49, 1?56) 0?43 418 0?89 (0?49, 1?62) 0?71
Venous thromboemboli (VTE) 497 0?77 (0?22, 2?67) 0?68 419 0?53 (0?11, 2?34) 0?4
Ever transfused 487 1?28 (0?53, 3?12) 0?58 413 1?46 (0?60, 3?58) 0?41
On iron treatment (oral) 489 1?28 (0?70, 2?34) 0?41 413 1?14 (0?60, 2?15) 0?68
Ever used intravenous iron 482 1?41 (0?39, 5?17) 0?6 407 1?31 (0?35, 4?85) 0?69
Ever used tranexamic acid 482 0?99 (0?21, 4?6) 0?99 407 1?22 (0?25, 5?98) 0?8
Ever used female hormones 480 1?41 (0?64, 3?14) 0?4 405 1?47 (0?64, 3?40) 0?37
Oxygen saturation erect (SaO2){ 471 0?98 (0?93, 1?02) 0?28 398 0?96 (0?92, 1?01) 0?085
Haemoglobin (g/dl) 464 1?00 (0?99, 1?02) 0?38 410 0?98 (0?91, 1?05) 0?62
Platelets 465 1?00 (1?00, 1?00) 0?67 415 1?00 (1.00, 1.00) 0?48
Serum iron { 419 0?96 (0?92, 1?00) 0?036 — — —
Transferrin saturation index (TfSI) 420 0?99 (0?97, 1?01) 0?17 418 1?00 (0?95, 1?06) 0?93
Ferritin 242 1?00 (0?99, 1?01) 0?91 236 1?00 (0?99, 1?01) 0?74
C-reactive protein 310 1?03 (1?00, 1?07) 0?06 292 1?03 (0?99, 1?06) 0?1
Prothrombin time 439 1?08 (0?96, 1?21) 0?2 394 1?02 (0?87, 1?20) 0?83
Activated partial thromboplastin time 435 0?97 (0?87, 1?07) 0?54 391 1?00 (0?90, 1?11) 0?97
Thrombin time 421 1?14 (0?97, 1?38) 0?11 379 1?13 (0?96, 1?34) 0?14
Fibrinogen 439 1?24 (1?00, 1?53) 0?048 393 1?16 (0?91, 1?47) 0?25
Factor VIII 280 1?45 (0?95, 2?30) 0?089 263 1?24 (0?78, 1?96) 0?36
von Willebrand Factor 202 1?09 (0?97, 1?23) 0?14 188 0?99 (0?70, 1?40) 0?95
Pulmonary artery pressure (systolic) 262 0?99 (0?94, 1?04) 0?71 221 0?97 (0?92, 1?03) 0?39
Pulmonary artery pressure (diastolic) 262 0?96 (0?88, 1?06) 0?45 221 0?96 (0?87, 1?06) 0?44
Pulmonary artery pressure (mean) 259 0?96 (0?89, 1?04) 0?3 218 0?94 (0?86, 1?03) 0?17
Series indicator 497 0?79 (0?54, 1?18) 0?23 419 0?73 (0?48, 1?10) 0?13
Full list of age/gender, and serum iron-adjusted odds ratios for ischaemic stroke risk for the specified variable, where an inverse association with stroke risk is indicated
by an odds ratio ,1. N: number of datasets available. CI, confidence intervals, AF, atrial fibrillation. Pseudo r2 indicates the proportion of stroke variance explained by
age, gender, and the specified variable. P values were calculated by the non parametric Wald test which does not assume independence of variables. { Quadratic
regression plots for stroke risk versus serum iron or SaO2 presented in Figure S1. Note p= 0.047 significant at FDR = 0.05 level.
doi:10.1371/journal.pone.0088812.t005
PAVMs and Strokes
PLOS ONE | www.plosone.org 8 February 2014 | Volume 9 | Issue 2 | e88812
Figure 2. Stroke incidence. A) Cumulative survival until first stroke: The solid line is modelled from the 129 patients with serum iron ,8 mmol/L;
dotted line from the 161 patients with serum iron.19 mmol/L. Shaded areas indicate 95% confidence intervals. B) Comparison of the stroke risk ROC
models from myocardial infarction and serum iron (base model, black line/symbols), and strongest model generated from captured physiological
variables, excluding the outcome measure of myocardial infarction (red line/symbols). The two models provide equivalent areas under the curve of
0.65 and 0?66 (p = 0.88). In the physiological ROC model, stroke risk was higher not only with lower serum iron (OR 0.95 [95% CI 0.90, 1.01]), but also
with lower PAP(mean) (OR 0.94 [0.86, 1.03]); higher fibrinogen (OR 1.50 [0.95, 2.33]), lower SaO2 (OR 0.98 [95% CI 0.93, 1?03]), and in women (OR 1.57
[0.71, 3.47]).
doi:10.1371/journal.pone.0088812.g002
Figure 3. Representative platelet dose response curves. A) Typical control and iron deficient responses to ADP at 5 (blue), 10 (green), 20 (red)
and 50 (black)mM. B) Typical control dose response curves to 5HT at 20 (blue), 200 (green), 2,000 (red) and 20,000 (black) mM–note the absence of the
secondary wave of aggregation. C) Representative 5HT dose response curves displaying delayed secondary wave of aggregation observed in all
severely iron deficient patients (hemoglobins 5.0–7.5 g/dl). The traces illustrated (5HT at 20 (blue), 200 (green), 2,000 (red) and 20,000 (black)) mM
were from an individual with ferritin 4 mg/L, iron 3 mmol/l, hemoglobin 7.5 g/dl. D) Traces from the same individual as in (C), following a 6 month
course of iron that resulted in improved iron indices (ferritin 31 mg/L, iron 7 mmol/l, hemoglobin 10.5 g/dl). Note that despite further treatments, iron
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Strengths of the current study include the lack of confounding
inflammatory diseases, and consistent assessment methodologies
including standardised timings of blood sampling which is
important because iron levels vary during the day. The absence
of arterial blood gas measurements of PaO2 may be considered a
weakness, but the reproducibility of the replicate pulse oximetry
SaO2 measurements (Table 1) render this criticism less important.
The similar haematinics defined by low serum iron, and the
Figure 4. Comparison of platelet dose response curves in response to agonists in iron deficient patients and controls. Solid lines
indicate controls; dotted lines represent the iron deficient group. Error bars represent standard error of the mean. A) Total aggregation in response to
ADP at 5–50 mmol/L. B) Rate of aggregation in response to ADP. Since circulating blood should spend less than two seconds between pulmonary
transits, the rate of aggregation may be particularly relevant. C) Total aggregation in response to 5HT. D) Rate of aggregation in response to 5HT.
doi:10.1371/journal.pone.0088812.g004
Table 6. Multiple regression analyses of 5HT-induced aggregation parameters.
Regression coefficient 95% confidence intervals P value
A) (Ln) total aggregation
5HT (mmol/L) 0.000036 6.861026, 0.000065 0.018
Ferritin (mg/L) 20.027 20.043, 20.011 0.002
Serum iron (mmol/L) 20.082 20.14, 20.028 0.005
Iron*ferritin (mg*mmol/L2): 0.0012 8.761026, 0.0024 0.052
B) (Ln) rate of aggregation
Ferritin (mg/L) 20.0062 20.010, 20.0022 0.004
Serum iron (mmol/L) 20.040 20.061, 20.019 0.001
A) The distribution for aggregation achieved was skewed and normalised by log transformation (Figure S2A). (Ln)aggregation was therefore used as the dependent
variable for regression. A model restricted to first order variables was not as strong as the final model including the iron-ferritin interaction term (iron*ferritin (mg*mmol/
L2)). This model of 24 assays explained 72% of the variance of (ln)aggregation (p = 0.0001). B) The distribution for rate of aggregation was skewed and normalised by log
transformation (Figure S2B). (Ln)rate of aggregation was therefore used as the dependent variable for regression. Final model for (ln)rate of aggregation in all 22
available assays, in a model that explained 77.4% of the variance (p,0.0001).The crude coefficient with iron was similar at 20.036 [95% CI 20.053, 20.0187], p,0.0001.
There was no relationship with 5HT concentration in univariate or iron/ferritin- adjusted regression (data not shown).
doi:10.1371/journal.pone.0088812.t006
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ferritin values conventionally used to define iron deficiency
(Table 2), support the use of both low serum iron and low ferritin
as markers of iron deficiency in the cohort in which ferritin levels
are often difficult to interpret due to concurrent conditions,
[61][62] particularly hepatic AVMs in HHT patients [60].
The data extend the previous studies on stroke risk in PAVM
patients, effectively analysing patients already within the higher
shunt grade shown by Velthius and colleagues to be associated
with enhanced risk of paradoxical embolic events. [18] Echocar-
diographic measurements were not made on the study population,
but the majority of patients in this study would be expected to have
a Grade 3 shunt, because they had PAVMs which were visible on
CT scans. Iron deficiency has not been proposed previously as a
risk factor for paradoxical embolic strokes in PAVM patients.
However, in the general population, the CVDSACTS cohort
study of 1,772 adults over 40 years, [72] NHANES I subgroup of
1,039 white women aged 45–74 ys, [73] and KLoSHA study of
965 Koreans aged over 65 years [74] all support an epidemio-
logical link between iron deficiency and ischaemic stroke risk
operating independently to known ischaemic stroke risk factors,
even if this was not the primary focus of the respective
reports.[72][74]
Iron deficiency in HHT results from under-replacement of iron
losses rather than the severity of haemorrhage per se, [34] but will
be more common in patients with greater haemorrhagic burdens
and therefore vascular damage. There are also innumerable
consequences of iron deficiency including anaemia/reduced blood
oxygen content, [51] high cardiac output with lower systemic
vascular resistance, [75][76][77] and increased blood viscosity.
[78] Additionally, in the HHT population, we recently demon-
strated that iron deficiency was associated with VTE, and elevated
Factor VIII. [60] We cannot exclude a role for these or other
processes in the pathogenesis of paradoxical embolic stroke,
though note there was no increase in VTE in patients with
ischaemic stroke, and no clear associations between ischaemic
stroke and polycythaemia, Factor VIII, or coagulation parameters
that would be shortened in venous prothrombotic states (Table 3,
Table 5). In the current study, there was an unexpected association
between ischaemic stroke and higher concentrations of fibrinogen,
the predominant circulating plasma protein for platelet adhesion.
[69] In general population studies, depletion of fibrinogen is
‘‘promising’’ in the treatment of acute ischaemic stroke. [79] In the
current study, the strokes resulted in only partial anterior or
posterior circulation syndromes. Taken together with the known
efficacy of anti-platelet agents in stroke prevention, [70] the
findings point towards a process influenced by paradoxical emboli
of small platelet aggregates in circulating blood.
There are few relevant data on circulating platelet aggregates,
[80] but platelet studies in the general population have demon-
strated higher spontaneous platelet aggregation in ischaemic stroke
patients. [81] The original association between iron deficiency and
enhanced aggregation to 5HT [64] has however, escaped notice:
PubMed searches in November 2013 for ‘‘iron,’’ ‘‘platelet(s),’’ and
{‘‘5HT’’ or ‘‘serotonin’’} retrieved no relevant results. 5HT is
usually studied with respect to neurotransmission, following release
from nerve tissue but is also released from the dense granules of
platelets and intestinal enterochromaffin cells. [69][71] 5HT
plasma concentrations increase after platelet activation, intestinal
ischaemia/reperfusion, drug administration, and in a number of
disease states including atherosclerosis. [69][71][80][82][83] The
importance of 5HT-platelet interactions remains controversial as
in the West, 5HT is considered a minor platelet agonist. However,
evidence particularly from Japan suggests greater importance:
Antagonists to the receptor 5HT2A result in dose-dependent
inhibition of platelet aggregation in ischaemic stroke patients, [80]
and achieved therapeutic equivalence with aspirin in secondary
prevention of ischaemic stroke. [83] Conversely, cardiovascular
side effects are recognised for drugs that increase extracellular
5HT/serotonin.[84]
The presented and published [64] data support a model in
which iron deficiency enhances platelet aggregation. We cannot
confirm a causal role to stroke pathogenesis- for example, it is
conceivable that iron deficiency is a marker of more severe
vascular damage that could be promoting platelet aggregation in
vivo, in addition to the vessel-independent effects observed with
iron deficient platelets ex vivo. Nevertheless, irrespective of the
precise mechanisms of formation, a proportion of platelet
aggregates which should lodge safely in pulmonary capillaries/
arterioles after forming or entering the venous circulation, would
escape pulmonary capillary filtration via the right-to-left shunts
provided by PAVMs, and instead occlude systemic arterioles/
capillaries including those of eloquent regions of the brain
(Figure 1C–F). The final outcome following impaction will depend
on local responses including orchestration of thrombo-inflamma-
tory cascades, [69] but during any thrombus resolution, systemic
tissues do not benefit from a separate arterial supply of oxygenated
blood, as in the lung.[1][3]
Our data do not allow us to say whether the stroke risk findings
would be more important than grading with contrast echocardio-
graphy - further studies could be conducted to assess if the iron
deficiency risk is greater in echo- stratified patients. However, for
patients with CT-proven PAVMs, the key biomarker for ischaemic
stroke risk appears to be iron deficiency, and not the severity of
right-to-left shunt. Iron deficiency is potentially reversible if iron
intake can be increased to meet demands,[34] and reassuringly, in
the current study, use of iron tablets to treat iron deficiency due to
HHT-related bleeding [34] was not associated with enhanced
stroke risk (Table 3, Table 5). Correction of iron deficiency is
however often difficult in HHT patients, due to ongoing
haemorrhagic blood losses. [22][23][24][34] The additional data,
albeit weak, that higher SaO2 is associated with a lower stroke risk
further supports the need for therapeutic embolisation to reduce
shunt size, while providing some reassurance to individuals with
smaller, untreatable, but CT-detectable PAVMs.
In summary, the data indicate that iron deficiency and
circulating platelets provide potentially novel opportunities for
targeted stroke reduction strategies that could be examined in
future clinical trials, particularly in the setting of compromised
pulmonary capillary filtration.
Supporting Information
Figure S1 Quadratic regression plots for continuous
variables associated with stroke risk. Quadratic regression
plots (with shaded intervals representing the 95% confidence
intervals) for continuous patient variables versus ischaemic stroke
risk for A) Serum iron; B) SaO2. Note the near-linear regression
lines, particularly for serum iron.
(TIF)
Figure S2 Normal quantile plots for platelet aggrega-
tion parameters used as dependent variables in regres-
sion analyses. A) Total aggregation across all concentrations of
5HT. Note skewed distribution. B) Rate of aggregation across all
concentrations of 5HT. Note skewed distribution. C) Log-
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